ELCC 2025 | Dr. Antonio Passaro Discusses TKI Combination Therapy as Standard First-Line Treatment for EGFR-Mutant NSCLC
At the 2025 European Lung Cancer Conference (ELCC), Professor Antonio Passaro from the European Institute of Oncology (IEO), Italy, led a deep discussion during the controversy session on the topic, "Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?"








